Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection
Hanh Thi Pham, Meng A Xiao, Miguel Av Principe, Alexander Wong, Thibault Mésplède
Abstract
, and limited clinical evidence suggests this to be the case in patients as well. Since K103N is by far the most prevalent (<70%) NNRTI substitution found in clinical practice, resistance against doravirine-based antiretroviral therapies is expected to be rare, even for treatment-experienced individuals. This review summarizes chemical, pharmacological, and clinical information about doravirine with an emphasis on drug resistance. The efficacy results from an early phase clinical trial evaluating doravirine in combination with islatravir are also provided.
Topics & Concepts
Reverse-transcriptase inhibitorLamivudineMedicineRegimenNucleoside Reverse Transcriptase InhibitorVirologyDrug resistanceNucleosideClinical trialPharmacologyHuman immunodeficiency virus (HIV)VirusSidaInternal medicineAntiretroviral therapyViral diseaseBiologyViral loadGeneticsHepatitis B virusHIV/AIDS drug development and treatmentHIV Research and TreatmentPneumocystis jirovecii pneumonia detection and treatment